Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
about
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) studyPredictors of Quality of Life in Acromegaly: No Consensus on Biochemical ParametersManagement of aggressive growth hormone secreting pituitary adenomas.The role of combination medical therapy in the treatment of acromegaly.Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas.Pasireotide in an insulin-requiring diabetic acromegalic patient without worsening of hyperglycemia.HMGA2 cooperates with either p27(kip1) deficiency or Cdk4(R24C) mutation in pituitary tumorigenesis.Pituicytoma-An outlook on possible targeted therapies.Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.
P2860
Q37578420-051D5ACA-5FD3-4341-9174-B3A6A507C7B5Q37678328-D566CCFE-67D6-4C5A-988C-624811052940Q38781620-FF7BA70C-C4BB-4B71-8765-D6BBE485920BQ38927318-EDCAD64B-8143-443C-A2EB-91E605058D56Q39024218-D6BBD6B3-0ACC-4857-9687-B3A917E3A539Q42243689-C35F9F31-59EC-41BC-BC97-F7FA55D1997FQ47382950-46517CD3-3241-45FE-A74A-D6886C9760DBQ47748900-9A2C5C19-0A5B-4EF8-B009-B8CDAAFA68C9Q54144943-3DDCACF8-3AB7-4E60-A531-56CC1094844BQ54939988-005EBDC8-1F7C-4949-B177-BE3D5D84AAC6
P2860
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Switching patients with acrome ...... double-blind, Phase III study.
@ast
Switching patients with acrome ...... double-blind, Phase III study.
@en
type
label
Switching patients with acrome ...... double-blind, Phase III study.
@ast
Switching patients with acrome ...... double-blind, Phase III study.
@en
prefLabel
Switching patients with acrome ...... double-blind, Phase III study.
@ast
Switching patients with acrome ...... double-blind, Phase III study.
@en
P2093
P2860
P1476
Switching patients with acrome ...... double-blind, Phase III study.
@en
P2093
Andrew J Farrall
Chiung-Chyi Shen
Karina Hermosillo Reséndiz
Marcello D Bronstein
Maria Fleseriu
Matthieu Ruffin
Michael Sheppard
Mônica Gadelha
Pamela Freda
P2860
P2888
P356
10.1186/S12902-016-0096-8
P577
2016-04-02T00:00:00Z
P5875
P6179
1029196717